Module

New Techniques and Management Options

Source: Prostate Cancer Annual Update 2006

New Techniques and Management Options

Program Director: E. David Crawford, MD

Faculty:
Daniel P. Petrylak, MD

CME CREDIT INFORMATION

Release Date: 03/22/06

Expiration Date: 03/21/07

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the latest clinical trial data that support the use of docetaxel-based therapy for the treatment of patients with hormone-refractory prostate cancer (HRPC)
Review the potential of new agents being tested for the treatment and management of HRPC
Describe the various techniques available for the treatment of localized prostate cancer

Topics covered include:

Introduction
Docetaxel-Based Therapy for HRPC
Bone-Targeted Therapy—Endothelin Receptor Antagonists
New Antimicrotubule Agents—Epothilones
Antiangiogenic Agents in Prostate Cancer
Calcitriol
Immunotherapy Approaches
Management of Clinically Localized Prostate Cancer
Other Management Options
Conclusions
Summary and Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.